Eupraxia Pharmaceuticals Inc. (EPRX) Stock Forecast
EPRX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 12 analysts
- Price target
- $16.35 average of analyst targets
- Upside to target
- +147.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.26
- 52-week range
- $5.33 – $9.10
EPRX analyst ratings
12 analystsNumber of analysts at each rating.
EPRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EPRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.26 | −$0.32 | −$0.22 | −$0.19 | −36.2% | 8 |
| Current fiscal year (2026) | −$0.97 | −$1.16 | −$0.78 | −$1.03 | +5.9% | 9 |
| Next fiscal year (2027) | −$1.04 | −$1.31 | −$0.38 | −$0.97 | −7.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EPRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $709,820 | $0 | $7.1M | 0.0% | 10 |
EPRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EPRX revenue: reported and forecast
EPRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.26 | −$0.26 | −$0.26 | −$0.26 | +5.9% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.97 | −$0.97 | −$0.97 | −$0.97 | −$0.97 | −0.6% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.90 | −$1.04 | −$1.04 | −$1.04 | −$1.04 | +15.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EPRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EPRX beat in 3 of 10.
What analysts expect from EPRX
12 analysts cover Eupraxia Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.35, 147.0% above the latest close of $6.62. Analysts expect earnings of −$0.97 per share for 2026, +5.9% from a year earlier. For 2027 the average estimate is −$1.04 per share on revenue of $0.7 million. Eupraxia Pharmaceuticals beat the EPS estimate in 3 of the last 10 quarters.
Related: EPRX income statement, EPRX key metrics, EPRX chart. See the EPRX stock overview for the latest quote and news.
EPRX forecast FAQ
What is Eupraxia Pharmaceuticals's price target?
The average analyst price target for Eupraxia Pharmaceuticals is $16.35, 147.0% above the latest close of $6.62.
Is Eupraxia Pharmaceuticals a buy, hold or sell?
Of 12 analysts covering Eupraxia Pharmaceuticals, 12 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eupraxia Pharmaceuticals's EPS forecast?
Analysts forecast −$0.97 per share for 2026 (range −$1.16 to −$0.78); for 2027 the estimate is −$1.04.
When does Eupraxia Pharmaceuticals report earnings?
Eupraxia Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-0.26.
Does Eupraxia Pharmaceuticals usually beat earnings estimates?
Eupraxia Pharmaceuticals reported EPS at or above the analyst estimate in 3 of the last 10 quarters.